GlassScriptPhysician profile
David R Levitan
NPI 1699751065
$16,874.88
in general payments reported to CMS, 2019-2025
31 companies · $619 in 2025
The $619 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $706 · 2020: $82.28 · 2021: $656 · 2022: $13K · 2023: $1,192 · 2024: $993 · 2025: $619.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,795 · Education: $9.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,794.73 |
| Education | $9.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Micro-Tech Endoscopy USA, INC. | $9,639.45 | 2019-2022 | |
| Abbvie INC. | $1,753.67 | 2019-2025 | |
| Ardelyx, INC. | $1,660.94 | 2022-2023 | Ibsrela |
| Janssen Scientific Affairs, LLC | $1,269.67 | 2019-2025 | Tremfya, Stelara, Remicade |
| Janssen Biotech, INC. | $355.32 | 2019-2025 | Stelara, Tremfya |
| E.R. Squibb & Sons, L.L.C. | $195.65 | 2022-2024 | Zeposia |
| Medtronic, INC. | $173.74 | 2021 | |
| Boston Scientific Corporation | $163.88 | 2021-2023 | Watchman Access System |
| Intercept Pharmaceuticals, INC. | $157.09 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $147.65 | 2019-2023 | Xifaxan |
| Lilly USA, LLC | $147.48 | 2023-2024 | Omvoh |
| Merck Sharp & Dohme LLC | $129.24 | 2020-2023 | Dificid |
| Braintree Laboratories, INC. | $125.12 | 2021-2024 | Sutab, Suflave |
| Takeda Pharmaceuticals U.S.A., INC. | $121.76 | 2019-2024 | Eohilia, Entyvio |
| Celgene Corporation | $100.16 | 2022-2024 | Zeposia |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $92.24 | 2023-2024 | |
| Ethicon US, LLC | $84.33 | 2019-2020 | |
| Organon LLC | $73.93 | 2022-2024 | |
| Daiichi Sankyo INC. | $68.67 | 2019-2023 | Injectafer |
| Pfizer INC. | $68.36 | 2019-2025 | |
| Qol Medical, LLC | $50.49 | 2019-2023 | Sucraid |
| Ferring Pharmaceuticals INC. | $48.20 | 2019-2023 | Rebyota |
| Vivus LLC | $48.00 | 2022-2024 | Qsymia |
| Aimmune Therapeutics, INC. | $47.81 | 2024 | |
| Amgen INC. | $44.04 | 2021-2023 | Avsola, Amjevita |
| Allergan, INC. | $33.00 | 2019 | |
| Nestle Healthcare Nutrition INC. | $30.85 | 2023 | |
| Perspectum Diagnostics LTD | $16.83 | 2022 | |
| Phathom Pharmaceuticals, INC. | $14.75 | 2024 | Voquezna |
| Ironwood Pharmaceuticals, INC | $12.56 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$65,805.25 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Levitan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.